ETFIQData as of Nov 18, 2026. · etfiq.com/funds/sixl

SIXL Fact Sheet: ETC 6 Meridian Low Beta Equity Strategy ETF

Share
$39.91
close, Nov 18, 2026

Over the year to Nov 18, 2026, SIXL returned +11.3% in total and charged 0.46% a year.

1-year total return
+11.3%
to Nov 18, 2026
Expense ratio
0.46%
a year
Net flow, 12 months to Aug 31, 2026
+$19.9m
monthly N-PORT basis to Aug 31, 2026

Growth of $10,000, 1 year

SIXL $11,130 +11.3% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+1.7%
3 months−0.4%
Year to date+12.0%
1 year+11.3%
3 years+33.9%
5 years+24.5%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
TG THERAPEUTICS, INC.0.77%
CORECIVIC, INC.0.74%
THE CHEFS' WAREHOUSE, INC.0.73%
Protagonist Therapeutics, Inc.0.66%
VIRTU FINANCIAL, INC.0.66%
HAEMONETICS CORPORATION0.66%
HALOZYME THERAPEUTICS, INC.0.65%
JOHN WILEY & SONS, INC.0.62%
Progyny, Inc.0.59%
SENSIENT TECHNOLOGIES CORPORATION0.59%

SIXL top ten by weight, 6.7% of the fund, of its 240 equity positions, from the holdings filed for Aug 31, 2026.

Facts

Equity fund · Actively managed · First traded May 11, 2020 · Benchmark Its own holdings, as of Aug 31, 2026; its prospectus names no index it tracks

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, SIXL Fact Sheet: ETC 6 Meridian Low Beta Equity Strategy ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/sixl/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/sixl.